Finance

Beta
Lists
RLAY:NASDAQ
Relay Therapeutics Inc
$18.02
+3.33%
(+0.58) 1D
$18.02
0.00% (0.00)
After hours
Closed: Jun 24, 4:00:02 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RLAY...
Open
$17.58
High
$18.83
Low
$17.54
Mkt. cap
3.88B
Avg. vol.
4.63M
Volume
4.60M
52-wk high
$18.83
52-wk low
$3.02
EPS
-$1.57
Beta
1.75
Shares outstanding
217.94M
No. of employees
193
Open
$17.58
High
$18.83
Low
$17.54
Mkt. cap
3.88B
Avg. vol.
4.63M
Volume
4.60M
52-wk high
$18.83
52-wk low
$3.02
EPS
-$1.57
Beta
1.75
Shares outstanding
217.94M
No. of employees
193
News stories
From sources across the web
About Relay Therapeutics Inc
CEO-
Employees193
Founded2015
Headquarters-
SectorBiotechnology
Websiterelaytx.com
Analyst Ratings
Based on 10 analysts giving stock ratings to RLAY in the past 3 months
Strong Buy
Buy
10
Hold
0
Sell
0
12 month forecast
Based on 10 Wall Street analysts offering 12 month price targets for RLAY in the last 3 months.
Highest
Current $18.02
$28.00 (+55.38%)
Average
$23.56 (+30.74%)
Lowest
$20.00 (+10.99%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Yaron Werber
TD Cowen
Buy
Reiterated
-
-
06/18/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$22.00
+22.1%
06/02/2026
Chi Meng Fong
Bank of America Securities
Buy
Maintained
$21.00
+16.5%
06/02/2026
Boris Peaker
JonesTrading
Buy
Reiterated
$20.00
+11%
06/02/2026
Bradley Canino
Guggenheim
Buy
Maintained
$26.00
+44.3%
05/25/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$28.00
+55.4%
05/26/2026
Silvan Tuerkcan
Citizens JMP
Buy
Maintained
$21.00
+16.5%
05/20/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Maintained
$21.00
+16.5%
05/19/2026
Etzer Darout
Barclays
Buy
Maintained
$27.00
+49.8%
05/20/2026
Sean McCutcheon
Raymond James
Buy
Maintained
$26.00
+44.3%
05/19/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$18.00
-0.1%
05/06/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$22.00
+22.1%
05/06/2026
Danya Ben-Hail
JonesTrading
Hold
Initiated
$18.00
-0.1%
04/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
677.00K
-
7.00M
3.00M
Cost of goods sold
61.47M
67.89M
56.34M
70.56M
Cost of revenue
61.47M
67.89M
56.34M
70.56M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.75M
12.50M
13.59M
11.03M
Operating expense
13.75M
12.50M
13.59M
11.03M
Total operating expenses
75.22M
80.39M
69.93M
81.59M
Operating income
-74.55M
-80.39M
-62.93M
-78.59M
Other non operating income
-633.00K
-165.00K
30.00K
-53.00K
EBT including unusual items
-70.38M
-74.15M
-54.89M
-73.29M
EBT excluding unusual items
-68.08M
-74.15M
-57.19M
-73.29M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-70.38M
-74.15M
-54.89M
-73.29M
Net profit margin
-10,395.13%
-
-784.14%
-2,443.03%
Earnings per share
-0.41
-0.43
-0.31
-0.41
Interest and investment income
7.10M
6.41M
5.71M
5.35M
Interest expense
-
-
-
-
Net interest expenses
7.10M
6.41M
5.71M
5.35M
Depreciation and amortization charges
-
-
-
-
EBITDA
-73.54M
-79.64M
-62.33M
-78.09M
Gain or loss from assets sale
615.00K
353.00K
35.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer